# CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome / Endometrial Atrophy / Thin Endometrium)

> **NCT07697924** · NA · RECRUITING · sponsor: **Fundación IVI** · enrollment: 35 (estimated)

## Conditions studied

- Asherman Syndrome

## Interventions

- **OTHER:** Umbilical cord platelet-rich plasma (hUC-PRP)

## Key facts

- **NCT ID:** NCT07697924
- **Lead sponsor:** Fundación IVI
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697924, "CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome / Endometrial Atrophy / Thin Endometrium)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*